Novozymes reports solid H1 figures despite bioenergy headwinds

Bioenergy was a heavy detractor in Novozymes' second quarter, according to a statement.

Photo: Martin Havtorn Petersen / Watch Medier

Log in to read our articles

Welcome to EnergyWatch. A part of our content is exclusive and reserved for our users.

Try EnergyWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles

Latest News


See all

See all